Weekly Issue — 2026-02-22

The word itself is awkward, and the authors know it. Coined roughly sixteen years ago as a counterpart to the genome, the exposome describes everything that is not your DNA: the air you have breathed since childhood, the water that has run through your taps, the noise that wakes you at 3 a.m., the heat your body has had to dissipate, plus the socioeconomic and lifestyle currents that shape all of it. The review frames this against a sobering backdrop. Chronic non-communicable diseases — heart disease chief among them — now account for roughly two-thirds of global deaths each year, driven both by an aging population and by the steady drip of environmental insults.

That number is not a forecast. It is the present tense.

The optimization crowd has spent the better part of two decades drilling down into the individual: genotype, biomarker, microbiome, sleep stage. The exposome literature pulls the camera back. It argues that the same body, placed in two different environments, will age along two different curves — and that the gap between those curves is not small.

Daiber and colleagues are careful not to oversell. Their review is a synthesis, not a randomized trial, and they note repeatedly that the exposome interacts with genetic predisposition and with diseases a person already has. A 70-year-old with well-controlled hypertension living near a busy freeway is not the same risk profile as a healthy 40-year-old in the same house. Vulnerability compounds.

Still, the through-line is consistent. Air pollution, traffic noise, contaminated water and soil, mental stress, and the rising temperatures of a changing climate are each associated with premature death and lost healthy life years, measured in the currency epidemiologists call disability-adjusted life years. The authors describe the exposome as having a specific external component (what you personally encounter) and a general external component (the broader social and economic conditions you live within), with finer subdivisions for organ-specific effects and for what they call the pollutome — the slice of exposure that is pollution, bounded in space and time.

It is worth being precise here, because the gap between a review paper and a tabloid headline is where most health confusion is born. The Atherosclerosis review consolidates observational and mechanistic evidence linking environmental exposures to cardiovascular disease. It discusses how the exposome is measured, what biomarkers researchers have identified, and how those biomarkers track with disease development and progression. It does not claim that moving house will subtract a decade from your cardiovascular age, and it does not propose a clinical protocol.

What it does suggest, with appropriate caution, is that a meaningful share of cardiovascular risk in older adults is environmental, modifiable in principle, and currently under-addressed in the way medicine is practiced and the way readers like you think about your own health. The evidence base, the authors note, is strongest for air pollution and noise; thinner, though growing, for soil contaminants and heat. We would rate the overall picture as moderate — convincing in aggregate, still maturing in the details.

If you are reading this magazine, you are probably already moving your body, watching your blood pressure, and at least skeptical of the supplement-of-the-month. The exposome literature is not an argument to abandon any of that. It is an argument to widen the field of view.

The practical implication, as we read it, is modest but real. A man in his sixties or seventies thinking carefully about the next twenty years might reasonably add to his mental checklist: what is the air like where I sleep, what is the noise like where I sleep, and how exposed am I to extreme heat in a summer that keeps getting hotter? None of these questions has a pill answer. All of them have an awareness answer, and some of them have a behavioral one — when to close a window, when to run a filter, when to stay indoors on a bad-air day, when to call the doctor if a heat wave is coming and you take a medication that affects how you handle it.

That last point matters. Anyone with established cardiovascular disease, or on medications that alter blood pressure, fluid balance, or heart rate, should treat decisions about heat, exertion, and air quality as medical questions, not lifestyle questions. The right person to walk through them with is your own clinician, who knows your history.

Sixteen years is a short life for a scientific concept. The exposome is still, in some ways, an organizing idea looking for the right tools to measure itself. But the direction of travel in the recent literature is clear enough: the environment is not background. It is a variable, and for cardiovascular risk in particular, it appears to be a sizeable one.

For a reader who has spent years tightening up the inside — diet, exercise, sleep, labs — the next frontier may be looking at the outside. Not as a reason to despair about what you cannot control, but as a reminder that some of the highest-leverage decisions about staying strong, sharp, and independent into your eighties may be quieter ones: where you sleep, what you breathe, and how seriously you take a hot week in July.

Clinicians who prescribe GLP-1s have known for years that response is uneven. Trial averages — the 15% or 20% weight-loss figures that make magazine covers — hide a wide distribution. Some patients sit at the top of the curve. Others lose almost nothing despite dutiful adherence, and end up wondering whether the failure is theirs.

A 2025 analysis published in Diabetes, Obesity & Metabolism offers one of the first credible biological explanations. Researchers mining the NIH All of Us cohort of more than 6,500 GLP-1 users built a genetic score around neurobeachin (NBEA), a gene encoding a protein kinase A anchor protein expressed heavily in the brain. People whose score crossed the "responsive" threshold were 82% more likely to be among the top weight-loss responders on liraglutide, a finding that held up when tested again in the UK Biobank. The same score also flagged a non-response signal: liraglutide users on the other end of the distribution were about 50% more likely to lose no weight at all.

The semaglutide signal was directionally similar but weaker, with odds ratios of roughly 1.6 in discovery and 2.2 in validation. That nuance matters. It suggests the genetic effect is real but drug-specific, and that NBEA alone will not become a clean yes-or-no test. What it does provide is a foothold — a first plausible mechanism for why the same dose lands so differently in different bodies.

A second 2025 study, this one a randomized trial of 100 adults with obesity, asks a quieter but equally important question: when GLP-1s improve metabolic markers, is the drug doing the work, or is the weight loss?

Participants were randomized to liraglutide plus metformin or metformin alone for 24 weeks, with standardized diet and exercise. Both groups improved; the GLP-1 group improved more. But when researchers looked specifically at proinsulin processing — a marker of how cleanly the pancreas converts its precursor hormone into mature insulin — the change tracked body-weight and visceral-fat reduction rather than GLP-1 exposure itself, even after adjusting for age, sex, baseline BMI and treatment arm.

The implication is subtle but useful. GLP-1s may be best understood, at least for some endpoints, as efficient delivery vehicles for weight loss rather than as drugs with broad standalone metabolic magic. That framing aligns with what many endocrinologists already suspected, and it sharpens expectations: a patient who loses little weight on a GLP-1 is unlikely to capture the full downstream metabolic benefit, regardless of how the drug is theoretically supposed to work.

If single-agent GLP-1s have a ceiling — set partly by genetics, partly by tolerability — the obvious next move is to stack mechanisms. Tirzepatide, which combines GLP-1 and GIP receptor activity in one molecule, already hints at the upside. The early pipeline is going further.

One example: VB-87531, a small-molecule inhibitor of MOGAT2, an enzyme involved in resynthesizing dietary triglycerides for transport to the liver. In diet-induced obese mice, VB-87531 reduced weight and food intake on its own. More interesting, when paired with either semaglutide or tirzepatide, the combination produced greater weight loss and appetite suppression than the MOGAT2 inhibitor alone, alongside lower insulin and leptin and higher FGF21 and PYY — a hormonal profile that, on paper, looks favorable.

The caveat is large and worth stating plainly: this is preclinical work in mice. The history of obesity pharmacology is littered with compounds that dazzled in rodents and disappointed in humans. VB-87531 is not a treatment; it is a hypothesis. But the underlying logic — combine a centrally acting appetite drug with a peripherally acting fat-handling drug — is exactly the direction the field is moving, and several similar pairings are in earlier human exploration.

None of this changes a prescription today. There is no NBEA test you can order, no MOGAT2 combination on a pharmacy shelf, and no guidance that the proinsulin finding should alter how a clinician chooses between liraglutide, semaglutide or tirzepatide. What is changing is the framing.

For readers already on a GLP-1, the most practical takeaway is that uneven response is biological, not a personal failing — and that the metabolic gains tend to follow the weight loss, which is why sticking with lifestyle scaffolding still matters even on a powerful drug. For readers considering one, it is worth asking your clinician how response will be monitored, what a reasonable trial period looks like, and what the plan is if you fall on the lower end of the curve. Those are the questions the next few years of research are designed to answer.

The GLP-1 story started as a blockbuster. It is quietly turning into something more interesting: a precision-medicine story, in which the right drug, the right combination and the right expectations may eventually be matched to the right patient.

For the looksmaxing crowd, muscle isn't vanity — it's architecture. It holds posture, fills a frame, and underwrites the kind of mobility that reads as youth long before any skincare routine does. Sarcopenia, the age-related loss of muscle mass and function, is the slow erosion under all of it. Which is why a recent dataset out of the Chinese Longitudinal Healthy Longevity Survey is worth a careful look: it ties a culturally adapted MIND-style eating pattern to lower odds of low muscle mass and better physical performance in community-dwelling older Chinese adults.

The investigators drew on 13,422 participants from the 2018 CLHLS wave and scored each one on a Chinese-modified MIND diet — call it cMIND — that swaps in foods more familiar to Chinese kitchens while preserving the original framework's emphasis on greens, whole grains, legumes, nuts, fish, and restraint around red meat and sweets. Muscle mass was estimated using a validated appendicular skeletal muscle mass formula rather than DEXA, and physical performance was captured with a four-item scale referencing SARC-F, the standard sarcopenia screening tool. Logistic and linear regression models, adjusted for sociodemographic, lifestyle, and health confounders, did the heavy lifting on the analysis.

The headline finding: participants in the highest tertile of cMIND adherence had roughly 21% lower odds of low muscle mass compared with those in the lowest tertile (OR 0.79), after full adjustment. Physical performance scores also tracked higher with stronger adherence. Across subgroup and sensitivity analyses, the direction of the association held.

The mechanism story is intuitive even if it isn't proven here. The cMIND pattern is dense in polyphenols, omega-3s, fiber, and plant protein — inputs that, in other literature, have been associated with lower systemic inflammation and better anabolic signaling in aging muscle. The pattern also displaces the ultra-processed calories that crowd out protein and micronutrients in many older adults' diets. None of that mechanism is litigated by this paper; the authors report associations, not pathways.

That distinction matters. Cross-sectional data can show that people who eat this way also have more muscle and better function. It cannot show that the eating built the muscle. Healthier eaters tend to move more, sleep better, and have more resources — confounders the authors adjusted for, but cannot fully neutralize.

Read this honestly and the takeaway is modest but real: a Mediterranean-leaning, plant-forward, fish-friendly pattern is now associated with muscle preservation in a very large Asian cohort, not just cognitive outcomes in Western ones. That broadens the evidence base for treating the MIND template as a general aging-well play rather than a brain-only one. For readers building a long-horizon appearance and function stack, food choice is upstream of almost everything that shows on a body — skin tone, fullness, posture, gait.

What this paper does not justify: claiming the cMIND diet builds muscle, treating it as a substitute for resistance training and adequate protein intake, or extrapolating odds ratios from older Chinese adults to a thirty-year-old optimizer. The protein and training side of sarcopenia prevention remains the load-bearing wall; diet pattern is the frame around it.

The premium move here isn't to chase a new acronym. It's to notice that the same unfussy, plant-forward, fish-and-greens-and-whole-grains template keeps showing up at the top of the leaderboard across cognition, cardiometabolic risk, and now — tentatively — muscle. That convergence is the actual story. The body, it turns out, prefers a coherent strategy.